Lilly Humatrope for short stature
Executive Summary
Lilly's Humatrope (somatropin rDNA origin) supplemental NDA (19-604/S-033) for treatment of non-growth hormone deficiency short stature will be considered by FDA's Endocrinologic & Metabolic Drugs Advisory Committee on June 10. Studies have shown that growth hormone treatment in children with idiopathic short stature and normal GH levels may increase height by 4-6 cm over controls. The meeting will be held at the Holiday Inn in Bethesda, Md. beginning at 8:30 a.m...
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.